Skip to Content

DexCom Inc DXCM

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Dexcom Sees Strength in First Quarter That Should Continue Upon European Launch of G7 by End of Year

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

No-moat Dexcom posted strong first-quarter performance that was largely in line with our expectations for the full year. However, after dialing up our expectations for the impending launch of next-generation G7, we plan to modestly raise our fair value estimate. Shares remain overvalued, from our perspective. The firm continues making progress toward navigating the regulatory path to commercializing G7. We anticipate the firm will file for European regulatory approval shortly, and management remains firm that Dexcom should launch in that geography by the end of this year. Additionally, with the U.S. pivotal trial set to wrap up this summer, we could see G7 launch domestically in the second half of 2022. Considering Dexcom has firmly crossed over into profitability, we think it’s appropriate to reexamine whether the firm has dug a moat for itself. At first blush, we think there may be an argument for intangible assets--specifically the firm’s ability to innovate and offer superior accuracy in its continuous glucose monitors.

Read Full Analysis

Company Profile

Business Description

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Contact
6340 Sequence Drive
San Diego, CA, 92121
T +1 858 200-0200
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 6,400

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.